Topical Imiquimod for Bowen's Disease of the Head and Neck
Phase III Trial of 6 Weeks of Imiquimod for the Treatment of Bowens Disease of the Head and Neck. Outcome is Histologic Clearance at 14 Weeks.
Sponsor: Brooke Army Medical Center
A PHASE2/PHASE3 clinical study on Bowens Disease, this trial is ongoing. The trial is conducted by Brooke Army Medical Center and has accumulated 6 data snapshots since 2006. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2/PHASE3
Status: Unknown Status → Unknown · Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE2_PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE2_PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Unknown Status PHASE2_PHASE3
Status: Enrolling By Invitation → Unknown Status
▶ Show 1 earlier version
-
Jan 2017 — Feb 2017 [monthly]
Enrolling By Invitation PHASE2_PHASE3
First recorded
Nov 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Brooke Army Medical Center
For direct contact, visit the study record on ClinicalTrials.gov .